The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease - Vigipallia

0 avis

The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease

Archive ouverte

Sollelis, E. | Quinard, R. Minet | Bouguen, G. | Goutte, Marion | Goutorbe, F. | Bouvier, D. | Pereira, B. | Bommelaer, G. | Buisson, A.

Edité par CCSD ; Oxford University Press -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Faecal calprotectin as surrogate marker of transmural healing assessed using MRI in patients with Crohn's disease

Archive ouverte | Allimant, C. | CCSD

International audience

Comparison between faecal chitinase 3-like 1, matrix metalloprotease 9, and calprotectin to assess mucosal healing in Crohn's disease: a multicentre prospective study

Archive ouverte | Buisson, A. | CCSD

International audience

Definition of therapeutic response criteria using MRI in Crohn's disease patients treated with anti-TNF therapy: a multicenter prospective study (the IRMA study)

Archive ouverte | Buisson, A. | CCSD

International audience

Chargement des enrichissements...